Dr. Bachmeyer's daily BPC-157 claims don't match the science

What did @drtrevorbachmeyer actually say?

The creator claims he takes BPC-157 every day and will "pretty much forever," calling it "the easiest longevity peptide anybody could ever use." He walks through five proposed mechanisms: angiogenesis via VEGF upregulation, TGF-beta signaling for structural repair, growth hormone receptor sensitization in the brain, cytokine modulation (suppressing TNF-alpha, promoting IL-10), and nitric oxide stimulation. Then he goes further, claiming BPC-157 "solves" leaky gut, IBD, ulcerative colitis, Crohn's disease, gastric ulcers, tendinopathies, liver damage, and post-surgical healing. His closing argument is that your body's repair capacity is the top predictor of longevity, and BPC-157 directly signals those repair mechanisms to stay active as you age.

Does the science back this up?

Some of the mechanistic biology is real. The clinical evidence in humans is not. BPC-157 has a legitimate preclinical research record, but virtually all of it is in rodents. No large randomized controlled trials in humans exist to validate the disease-level claims he makes.

The angiogenesis and VEGF angle has support in animal models. Sikiric et al. (2018, Current Pharmaceutical Design) documented VEGF pathway involvement in rat wound healing studies. TGF-beta involvement in fibroblast activation is a real mechanism described in connective tissue biology, though BPC-157's specific role in humans isn't established. The nitric oxide connection also appears in preclinical literature. Chang et al. (2011, Journal of Applied Physiology) showed BPC-157 influenced nitric oxide pathways in rat models of muscle injury. The growth hormone receptor sensitization claim is the weakest. There is limited, low-quality preclinical data on this, and extrapolating it to human brain repair is speculative.

What did they get wrong (or right)?

He gets credit for the basic biochemistry framing. The five mechanisms he names are not invented, they appear in preclinical literature. But the leap from "this happens in rats" to "this solves Crohn's disease" is not a small one. It is the entire difference between a hypothesis and a treatment.

Saying BPC-157 "solves" ulcerative colitis, Crohn's, and liver damage is flatly unsupported by human clinical data. That is not a conservative reading of the evidence. That is the evidence. The FDA has not approved BPC-157 for any indication. It is not an FDA-cleared drug. Using language like "this isn't theoretical" when the human evidence does not exist is misleading to the roughly 28,500 people who watched this video, many of whom may have IBD or chronic tendon injuries and are looking for real answers.

His cytokine framing (TNF-alpha down, IL-10 up) reflects real findings in rodent inflammatory models. Huang et al. (2015, PLOS ONE) documented anti-inflammatory effects in rat colon injury. But characterizing it as the compound being "smart enough to know the difference" anthropomorphizes a peptide in a way that oversimplifies complex immune biology.

What should you actually know?

BPC-157 is a synthetic peptide derived from a protein found in gastric juice. It is not FDA-approved. It is available through compounding pharmacies in the US under specific conditions, but it sits in a regulatory gray zone. The compound is currently on the FDA's list of substances that cannot be compounded under section 503A, which matters if you are considering sourcing it.

The preclinical data is genuinely interesting. Animal studies suggest real biological activity in healing pathways. But interesting preclinical data has failed to translate to human outcomes more times than anyone in medicine cares to count. Peptide therapy as a category is under-studied in humans, and that gap between animal models and clinical validation is exactly where patients get hurt, financially and physically.

• No phase III human trials on BPC-157 exist as of 2024.
• Long-term safety data in humans is essentially nonexistent.
• VEGF upregulation, which he frames as purely beneficial, can theoretically support tumor angiogenesis. This is not a settled risk, but it is not zero.
• If you have IBD, Crohn's, or a tendon injury, talk to a licensed clinician before adding any peptide to your regimen. Animal data is not a treatment plan.